Механизмы цитотоксического действия оловоорганических соединений

В обзоре проанализированы данные, представленные в доступной нам медицинской и научной литературе, посвященные доклиническому изучению in vitro цитотоксических свойств оловоорганических соединений (ООС), а также основных механизмов их действия. Последние, в частности, заключаются во взаимодействии со свободными SH группами белков, инициировании окислительного стресса, связывании с ДНК, взаимодействии с рецепторами, а также активированием апоптоза за счет повышения экспрессии каспаз, проапоптотических белков и уменьшением антиапоптотического белка. В зависимости от донорного лиганда ООС проявляют специфическую цитотоксичность по отношению к опухолевой клеточной линии. Высокий цитотоксический потенциал ООС указывает на целесообразность их дальнейшего изучения in vivo и разработки в качестве кандидатов для создания лекарственных средств для противоопухолевой и антиметастатической терапии.

1. Зуева Е.П., Разина Т.Г., Амосова Е.Н., Лопатина К.А., Рыбалкина О.Ю., Сафонова Е.А. Скрининговые исследования на животных в онкофармакологии: право насуществование. Информационныетехнологиивмедицине, биологии, фармакологии и экологии: мат-лы Межд. конф. 2018:121–125.

2. Мухатова Е.М., Осипова В.П., Коляда М.Н., Мовчан Н.О., Шпаковский Д.Б., Грачева Ю.А., Орлова С.И., Милаева Е.Р. Синтез и антиоксидантная активность новых оловоорганических соединений, содержащих фрагмент 2,6-ди-трет-бутилфенола. Доклады Академии наук. 2013;451(1):46–49.

3. Alama A., Tasso B., Novelli F., Sparatore F. Organometallic compounds in oncology: Implications of novel organotins as antitumor agents. Drug Discov. Today. 2009;14:500–508. DOI: 10.1016/j. drudis.2009.02.002.

4. Antonenko T.A., Shpakovsky D.B., Berseneva D.А., Gracheva Yu A., Dubova L.G., Shevtsov P.N., Redkozubova O.M., Shevtsova E.F., Tafeenko V.A., Aslanov L.A., Milaeva E.R. Cytotoxic activity of organotin carboxylates based on synthetic phenolic antioxidants and polycyclic bile acids. J. Organomet. Chem. 2020;909:121089. DOI: 10.1016/j.jorganchem.2019.121089.

5. Antonenko T.A., Shpakovsky D.B., Vorobyov M.A., Gracheva Yu A., Kharitonashvili E.V., Dubova L.G., Shev tsova E.F., Tafeenko V.A., Aslanov L.A., Iksanova A.G., Shtyrlin Yu.G., Milaeva E.R. Antioxidative vs cytotoxic activities of organotin complexes bearing 2,6-di-tert-butylphenol moieties. Appl. Organomet. Chem. 2018;32(7):e4381. DOI: 10.1002/aoc.4381.

6. Arshad N., Bhatti M.H., Farooqi S.I., Saleem S., Mirza B. Synthesis, photochemical and electrochemical studies on triphenyltin (IV) derivative of (z)-4-(4-cyanophenylamino)-4-oxobut-2-enoic acid for its binding with DNA: Biological interpretation. Arab. J. Chem. 2016;9(3):451– 462. DOI: 10.1016/j.arabjc.2014.08.018.

7. Assunta Girasolo M., Attanzio A., Sabatino P., Tesoriere L., Rubino S., Stocco G. Organotin(IV) derivatives with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidine and their cytotoxic activities: The importance of being conformers, Inorg. Chim. Acta. 2014;423:168–176. DOI: 10.3390%2Fmolecules25040859.

8. Balas V.I., Verginadis I.I., Geromichalos G.D., Kourkoumelis N., Male L., Hursthouse M.B., Repana K.H., Yiannaki E., Charalabopoulos K., Bakas T. Synthesis, structural characterization and biological studies of the triphenyltin(IV) complex with 2-thiobarbituric acid. Eur. J. Med. Chem. 2011;46(7):2835–2844. DOI:10.1021/ic061601f.

9. Banti C.N., Hadjikakou S.K., Sismanoglu T., Hadjiliadis N. Anti-proliferative and antitumor activity of organotin(IV) compounds. An overview of the last decade and future perspectives. J. Inorg. Biochem. 2019;194:114–152. DOI:10.1016/j. jinorgbio.2019.02.003.

10. Basu Baul T.S., de Vos D. In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene) arylamine]tin(IV) derivatives in human tumor cell lines. Investig. New Drugs. 2010;28:609–614. DOI: 10.1007/s10637-009-9300-2.

11. Bouâlam M., Meunier-Piret J., Biesemans M., Willem R., Gielen M. Organotin (IV) compounds of 2-thiopyridine. crystal and molecular structure of dicyclohexyltin (iv) bis(2-pyridylthiolate). Inorg. Chim. Acta. 1992;198(200):249–255. DOI: 10.1016/ S0020-1693(00)92367-3.

12. Davies A.G., Smith P.J. Tin in comprehensive organometallic chemistry. Ed. by: G. Wilkinson, F.A.S. Gordon, E.W. Abel. Oxford: Pergamon Press, 1982. 519 p.

13. Fickova M., Macho L., Brtko J. A comparison of the effects of tributyltin chloride and triphenyltin chloride on cell proliferation, proapoptotic P53, bax, and antiapoptotic Bcl-2 protein levels in human breast cancer MCF-7 cell line. Toxicol. In Vitro. 2015; 29(4):727–731. DOI: 10.1016/j.tiv.2015.02.007.

14. Galván-Hidalgo J.M., Chans G.M., Ramírez-Apan T., Nieto-Camacho A., Hernández-Ortega S., Gómez E. Tin (IV) schiff base complexes derived from pyridoxal: synthesis, spectroscopic properties and cytotoxicity. Appl. Organomet. Chem. 2017;31(9):e3704. DOI: 10.1002/aoc.3704.

15. Gasser G., Metzler-Nolte N. The potential of organometallic complexes in medicinal chemistry. Curr. Op. Chem. Biol. 2012;16:84–91. DOI: 10.1016/j. cbpa.2012.01.013.

16. González A., Gómez E., Cortés-Lozada A., Hernández S., Ramírez-Apan T., Nieto-Camacho A., Heptacoordinate tin(IV) compounds derived from pyridine schiff bases: synthesis, characterization, in vitro cytotoxicity, anti-infl ammatory and antioxidant activity. Chem. Pharm. Bull. (Tokyo). 2009;57:5–15. DOI: 10.1248/cpb.57.5.

17. Grześkiewicz A.M., Owczarzak A., Kucińska M., Murias M., Kubicki M. Structural peculiarities and anticancer activities of two organotin compounds. J. Coord. Chem. 2017;70(10):1776-1789. DOI:10.1080/ 00958972.2017.1316841.

18. Hadjikakou S.K., Hadjiliadis N. Antiproliferative and anti-tumor activity of organotin compounds. Coord. Chem. Rev. 2009;253:235–249. DOI: 10.1016/j. ccr.2007.12.026.

19. Jenkins R.O., Craig P.J., Francesconi K.A., Harrington C.F. Environmental and biological aspects of organometallic compounds. Ed. by O’Hare. Comprehensive Organometallic Chemistry III. Oxford: Elsevier. 2006;11:603–661.

20. McCombe Roark A. Endocrine disruptors and marine systems. Ref. Mod. Earth Sys. Env. Sci., Encyclopedia of the World’s Biomes, Elsevier Inc. 2020;188–194.

21. Metsios A., Verginadis I., Simos Y., Batistatou A., Peschos D., Ragos V., Vezyraki P., Evangelou A., Karkabounas S. Cytotoxic and anticancer effects of the triorganotin compound [(C6 H5 ) 3 Sn(Cmbzt)]: An in vitro, ex vivo and in vivo study. Eur. J. Pharm. Sci. 2012;47(2):490–496. DOI: 10.1016/j.ejps.2012.07.011.

22. Mushak P., Krigman M.R., Mailman R.B. Comparative organotin toxicity in the developing rat: somatic and morphological changes and relationship to accumulation of total tin. Neurobehav. Toxicol. Teratol. 1982;4(2):209–215.

23. Nakanishi T. Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor. J. Toxicol. Sci. 2008;33(3):269– 276. DOI:10.2131/jts.33.269.

24. Navakoski de Oliveira K., Andermark V., Onambele L.A., Dahl G., Prokop A., Ott I. Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells. Eur. J. Med. Chem. 2014;87:794–800. DOI:10.1016/j. ejmech.2014.09.075.

25. Pellerito C., Nagy L., Pellerito L., Szorcsik A. Biological activity studies on organotin(IV)n+- complexes and parent compounds. J. Organomet. Chem. 2006;691:1733–1747. DOI:10.1016/j.jorganchem.2005.12.025.

26. Pellerito L., Nagy L. Organotin (IV)n+complexes formed with biologically active ligands: Equilibrium and structural studies, and some biological aspects. Coord. Chem. Rev. 2002;224:111–150. DOI: 10.1016/S0010- 8545(01)00399-X.

27. Phillips R.S. Chemistry and diversity of pyridoxal5’-phosphate dependent enzymes. Biochim. Biophys. Acta. 2015;1854(9):1167–1174. DOI:10.1016/j. bbapap.2014.12.028.

28. Rehman W., Yasmeen R., Rahim F., Waseem M., Guo C.-Y., Hassan Z., Rashid U., Ayub K., Synthesis biological screening and molecular docking studies of some tin (IV) Schiff base adducts. J. Photochem. Photobiol. 2016;164:65–72. DOI: 10.1016/j. jphotobiol.2016.09.018.

29. Shang X., Zhao B., Xiang G., Guedes da Silva M.F.C., Pombeiro A.J.L. Dimeric diorganotin (IV) complexes with arylhydrazones of β-diketones: synthesis, structures, cytotoxicity and apoptosis properties. RSC Adv. 2015;5:45053–45060. DOI:10.1039/C5RA06658A.

30. Shi P.-F., Jiang Q., Duan H.-C., Wang D.-Q. Synthesis, characterization and cytotoxicity of fl uorescent organotin complexes of terpyridine derivatives. Chin. Chem. Lett. 2014;25:586–588. DOI:10.1016/j. cclet.2014.01.049.

31. Shpakovsky D.B., Banti C.N., Beaulieu-Houle G., Kourkoumelis N., Manoli M., Manos M.J., Tasiopoulos A.J., Hadjikakou S.K., Milaeva E.R., Charalabopoulos K., Bakas T., Butler I.S., Hadjiliadis N. Synthesis, structural characterization and in vitro inhibitory studies against human breast cancer of the bis-(2,6-di-tert-butylphenol)tin(IV) dichloride and its complexes. Dalton Trans. 2012;41:14568–14582. DOI:10.1039/C2DT31527K.

32. Shpakovsky D.B., Banti C.N., Mukhatova E.M., Gracheva Yu A., Osipova V.P., Berberova N.T., Albov D.V., Antonenko T.A., Aslanov L.A., Milaeva E.R., Hadjikakou S.K. Synthesis, antiradical activity and in vitro cytotoxicity of novel organotin complexes based on 2,6-di-tert-butyl-4-mercaptophenol. Dalton Trans. 2014;43(18):6880–6890. DOI: 10.1039/ C3DT53469C.

33. Stohs S.J., Bagchi D. Oxidative Mechanisms in the Toxicity of Metal Ions. Free Rad. Biol. Med. 1995;18(2):321–336. DOI:10.1016/0891- 5849(94)00159-h.

34. Tabassum S., Khan R.A., Arjmand F., Sen S., Kayal J., Juvekar A.S., Zingde S.M. Synthesis and characterization of glycoconjugate tin (IV) complexes: in vitro DNA binding studies, cytotoxicity, and cell death. J. Organomet. Chem. 2011;696(8):1600–1608. DOI:10.1016/j.jorganchem.2011.01.012.

35. Tabassum S., Yadav S., Arjmand F., Exploration of glycosylated-organotin (IV) complexes as anticancer drug candidates. Inorg. Chim. Acta. 2014;423:38–45. DOI:10.1016/j.ica.2014.07.080.

36. Verginadis I., Karkabounas S., Simos Y., Kontargiris E., Hadjikakou S.K., Batistatou A., Evangelou A., Charalabopoulos K. Anticancer and cytotoxic effects of a triorganotin compound with 2-mercapto-nicotinic acid in malignant cell lines and tumor bearing Wistar rats. Eur. J. Pharm. Sci. 2011;42(3):253– 261. DOI: 10.1016/j.ejps.2010.11.015.

37. Verginadis I., Metsios A., Simos Y., Batistatou A., Peschos D., Ragos V., Vezyraki P., Evangelou A., Karkabounas S. Cytotoxic and anticancer effects of the triorganotin compound [(C6H5)3Sn(cmbzt)]: an in vitro, ex vivo and in vivo study. Eur. J. Pharm. Sci. 2012;47(2):490–496. DOI: 10.1016/j. ejps.2012.07.011.

38. Zhang Y.-Y., Zhang R.-F., Zhang S.-L., Cheng S., Li Q.-L., Ma C.-L. Syntheses, structures and antitumor activity of four new organotin(IV) carboxylates based on 2-thienylselenoacetic acid. Dalton Trans. 2016;45:8412–8421. DOI:10.1039/c6dt00532b.